Worldwide Clinical partners with Cybin for psychedelic-based treatments

Worldwide Clinical Trials has signed a partnership with Cybin, a biopharma developing psychedelic-based treatment options for mental health issues.

Worldwide was tapped by Cybin because of the CRO’s patient recruitment success for psychedelic trials, according to a July 26 press release. Worldwide has managed 11 psychedelic studies in psychiatric populations, including phase 1 and phase 2 clinical trials conducted in the U.S., Canada, the U.K. and other European countries, covering a range of psychedelic compounds and treatment models.

Financial terms of the collaboration weren’t disclosed.

Last August, Worldwide completed a 15,000-square-foot expansion of its large-molecule laboratory in Texas that brought the facility to a total of about 60,000 square feet. The company said at the time the project would help reach a sample analysis scale of about 70,000 annually, which is forecast to grow to about 200,000 by 2024.

Worldwide’s scientific team also develops assays for popular large-molecule drug modalities like monoclonal antibodies, bispecifics, antibody-drug conjugates and fusion proteins.